2017 AHA科学声明:成人先天性心脏病患者非心脏并发症的诊断和管理

2017-10-09 美国心脏协会 Circulation. 2017 Oct 9.

2017年10月,美国心脏协会(AHA)发布了成人先天性心脏病患者非心脏并发症的诊断和管理声明,文章主要介绍了先天性心脏病患者并发肾脏,肺,肝脏,免疫以及感染性疾病,血液疾病,内分泌疾病,肿瘤,血管疾病和非心脏手术的诊断和管理等内容。

中文标题:

2017 AHA科学声明:成人先天性心脏病患者非心脏并发症的诊断和管理

英文标题:

Diagnosis and Management of Noncardiac Complications in Adults With Congenital Heart Disease: A Scientific Statement From the American Heart Association.

发布机构:

美国心脏协会

发布日期:

2017-10-09

简要介绍:

2017年10月,美国心脏协会(AHA)发布了成人先天性心脏病患者非心脏并发症的诊断和管理声明,文章主要介绍了先天性心脏病患者并发肾脏,肺,肝脏,免疫以及感染性疾病,血液疾病,内分泌疾病,肿瘤,血管疾病和非心脏手术的诊断和管理等内容。

 

拓展指南:先天性心脏病相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2017 AHA科学声明:成人先天性心脏病患者非心脏并发症的诊断和管理)] GetToolGuiderByIdResponse(projectId=1, id=294db1c00150ea58, title=2017 AHA科学声明:成人先天性心脏病患者非心脏并发症的诊断和管理, enTitle=Diagnosis and Management of Noncardiac Complications in Adults With Congenital Heart Disease: A Scientific Statement From the American Heart Association., guiderFrom=Circulation. 2017 Oct 9., authorId=null, author=, summary=2017年10月,美国心脏协会(AHA)发布了成人先天性心脏病患者非心脏并发症的诊断和管理声明,文章主要介绍了先天性心脏病患者并发肾脏,肺,肝脏,免疫以及感染性疾病,血液疾病,内分泌疾病,肿瘤,血管疾病和非心脏手术的诊断和管理等内容。 , cover=, journalId=null, articlesId=null, associationId=60, associationName=美国心脏协会, associationIntro=美国心脏协会(AHA,American Heart Association)是心脏病学领域比较正要的学会之一,致力于心脏病和卒中的预防与治疗,提供相关继续教育、流行病学年度报告。每年举办学术年会报道中的的临床试验结果等,有官方杂志《美国心脏协会杂志》,提供心血管疾病和卒中相关的指南及专家共识,更新的比较快。, copyright=0, guiderPublishedTime=Mon Oct 09 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>2017年10月,美国心脏协会(AHA)发布了成人先天性心脏病患者非心脏并发症的诊断和管理声明,文章主要介绍了先天性心脏病患者并发肾脏,肺,肝脏,免疫以及感染性疾病,血液疾病,内分泌疾病,肿瘤,血管疾病和非心脏手术的诊断和管理等内容。 </P> <P> </P>拓展指南:<strong>与<font color=red>先天性心脏病</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=bd26e1c001a3924f" title="【专题】先天性心脏病的防控,看看权威指南怎么建议" target=_blank>【专题】先天性心脏病的防控,看看权威指南怎么建议</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=0ab0e1c001a389db" title="新生儿危重先天性心脏病术前评估中国专家共识(草案)" target=_blank>新生儿危重先天性心脏病术前评估中国专家共识(草案)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=1e8071c001a051a8" title="2016 AHA科学声明:先天性心脏病患者的慢性心力衰竭" target=_blank>2016 AHA科学声明:先天性心脏病患者的慢性心力衰竭</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=3be501c0013e3641" title="2017AHA科学声明:复杂先天性心脏病患者妊娠管理" target=_blank>2017AHA科学声明:复杂先天性心脏病患者妊娠管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=488901c001330e1a" title="2016 ESC意见书:成人先天性心脏病患者心衰的治疗" target=_blank>2016 ESC意见书:成人先天性心脏病患者心衰的治疗</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E5%85%88%E5%A4%A9%E6%80%A7%E5%BF%83%E8%84%8F%E7%97%85" target=_blank>有关先天性心脏病更多指南</a></ul>, tagList=[TagDto(tagId=1808, tagName=先天性心脏病), TagDto(tagId=60926, tagName=非心脏并发症)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=1, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5902, appHits=157, showAppHits=0, pcHits=4320, showPcHits=1849, likes=159, shares=8, comments=5, approvalStatus=1, publishedTime=Sat Oct 14 23:39:11 CST 2017, publishedTimeString=2017-10-09, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sat Oct 14 23:39:11 CST 2017, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 02:31:23 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2017 AHA科学声明:成人先天性心脏病患者非心脏并发症的诊断和管理)])
2017 AHA科学声明:成人先天性心脏病患者非心脏并发症的诊断和管理
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=253357, encodeId=f47425335e62, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Oct 16 09:45:52 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253022, encodeId=695b253022b0, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Sun Oct 15 07:24:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252953, encodeId=5a9b252953a4, content=学习了很有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Oct 15 00:21:49 CST 2017, time=2017-10-15, status=1, ipAttribution=)]
    2017-10-16 Y—xianghai

    学习了新知识

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=253357, encodeId=f47425335e62, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Oct 16 09:45:52 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253022, encodeId=695b253022b0, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Sun Oct 15 07:24:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252953, encodeId=5a9b252953a4, content=学习了很有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Oct 15 00:21:49 CST 2017, time=2017-10-15, status=1, ipAttribution=)]
    2017-10-15 榄枷檬

    谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=253357, encodeId=f47425335e62, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Mon Oct 16 09:45:52 CST 2017, time=2017-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=253022, encodeId=695b253022b0, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAXaDEiaxhu025c3P0XshccTrbvGWBjKvnHIxbK3vqa80P7WGIFuicCFet97TicrNKpgB3TdabxP1vMh/0, createdBy=28851960965, createdName=榄枷檬, createdTime=Sun Oct 15 07:24:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252953, encodeId=5a9b252953a4, content=学习了很有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Oct 15 00:21:49 CST 2017, time=2017-10-15, status=1, ipAttribution=)]
    2017-10-15 飛歌

    学习了很有用

    0